Jennifer Brusca, P.T. Physical Therapist Medicare: Medicare Enrolled Practice Location: 181 Howard Blvd, Suite J, Mt Arlington, NJ 07856 Phone: 973-398-1601 Fax: 973-398-1602 |
Dr. Michael John Scarneo Jr., PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 181 Howard Blvd, Mt Arlington, NJ 07856 Phone: 973-398-1601 |
Terri Lynn Osbun, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2 Hillside Dr, Mt Arlington, NJ 07856 Phone: 973-601-0988 |
Mr. Michael L Sawyer, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 181 Howard Blvd Ste J, Mt Arlington, NJ 07856 Phone: 973-398-1601 Fax: 973-398-1602 |
News Archive
The Canadian Society of Palliative Care Physicians has developed a new staffing model for specialist palliative care teams that can deliver an optimal, integrated palliative care program.
A UNAIDS report released Tuesday at the 9th International Congress on AIDS in Asia and the Pacific (ICAAP) in Bali, Indonesia, estimates that more than 90 percent of the 1.7 million HIV-positive women living in Asia were infected by husbands or long-term partners who engaged in "high-risk sexual behaviours," Agence France-Presse reports. The UNAIDS report also found "women accounted for 35 percent of all adult HIV infections in Asia in 2008, up from 17 percent in 1990, the AFP writes.
GTx, Inc. today announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.
University of North Carolina Lineberger Comprehensive Cancer Center researchers are reporting the concluding findings from a major analysis of nearly 10,000 different tumor samples that focused on identifying similarities between cancers based on changes in their genes, and the way their genes are expressed.
Geron Corporation today announced that it has entered into a collaboration jointly funded by Geron and a University of California Discovery Research and Training Grant to investigate the therapeutic potential of its human embryonic stem cell (hESC)-based product, GRNOPC1, for Alzheimer's disease. The company is currently developing GRNOPC1 for the potential treatment of spinal cord injury.
› Verified 1 days ago